Agios Pharmaceuticals Balance Sheet
NASDAQ: AGIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Agios Pharmaceuticals financial position
At the end of fiscal 2025, Agios Pharmaceuticals reported total assets of $1.30 billion, down 22.0% from a year earlier against total liabilities of $104.1 million. Shareholders' equity stood at $1.19 billion, or 92.0% of assets. The company held $89.1 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 11.46, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Agios Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 89.13M | 76.25M | 88.20M | 139.26M | 203.13M | 127.44M | 80.93M | 70.50M | 102.72M | 160.75M |
| Short-Term Investments | 765.29M | 817.46M | 688.72M | 643.86M | 816.89M | 445.49M | 483.95M | 514.80M | 321.21M | 380.56M |
| Inventory | 32.92M | 27.62M | 19.08M | 8.49M | 0 | 14.70M | 7.33M | 869.00K | 0 | — |
| Total Current Assets | 942.05M | 965.60M | 833.84M | 832.77M | 1.06B | 636.68M | 611.70M | 613.78M | 445.26M | 559.89M |
| Property, Plant & Equipment | 10.78M | 11.68M | 15.38M | 22.99M | 28.92M | 30.82M | 31.47M | 24.32M | 24.43M | 25.34M |
| Long-Term Investments | 310.01M | 638.32M | 29.43M | 313.87M | 266.38M | 97.61M | 152.93M | 220.12M | — | — |
| Total Assets | 1.30B | 1.66B | 937.12M | 1.24B | 1.44B | 852.95M | 890.74M | 858.46M | 614.40M | 619.09M |
| Accounts Payable | 18.36M | 16.64M | 9.78M | 18.62M | 16.70M | 17.72M | 21.90M | 17.88M | 22.77M | 17.11M |
| Total Current Liabilities | 82.21M | 81.16M | 67.95M | 62.63M | 59.83M | 94.39M | 92.89M | 93.50M | 94.94M | 88.43M |
| Total Liabilities | 104.11M | 122.24M | 126.10M | 137.90M | 145.76M | 453.45M | 250.21M | 170.92M | 238.89M | 260.50M |
| Shareholders' Equity | 1.19B | 1.54B | 811.02M | 1.10B | 1.29B | 399.50M | 640.53M | 687.54M | 375.50M | 358.59M |
| Retained Earnings | -561.71M | -148.92M | -822.65M | -470.56M | -238.76M | -1.84B | -1.52B | -1.10B | -798.06M | -483.15M |
| Net Cash (Debt) | 854.42M | 893.71M | 776.93M | 783.12M | 1.02B | 572.93M | 564.88M | 585.30M | 423.94M | 541.31M |
| Shares Outstanding | 58.45M | 57.16M | 55.95M | 55.04M | 54.33M | 69.29M | 68.40M | 58.22M | 48.83M | 42.22M |
This table shows 10 annual periods of Agios Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, short-term investments, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow AGIO's reporting calendar. What is a balance sheet?